Status: Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Participants needed: 2,020
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Guardant Health, Inc.Updated: Aug 22, 2025Locations: 57
Eligibility criteria
Age > 18 years old AND [+16]
History of allogeneic organ or tissue transplant [+3]